Acute Antibody-Mediated Rejection in Liver Transplant Recipients with Autoimmune Liver Disease: A Clinical and Pathologic Study of 4 Cases.
Hongmei JiangHui GuoBo YangYuanyuan ZhaoLai WeiZhishui ChenDong ChenPublished in: Journal of personalized medicine (2022)
Background : Acute antibody-mediated rejection (AMR) is an uncommon complication after ABO-compatible liver transplantation (LT). This case series investigated the clinicopathologic characteristics and outcomes of acute AMR in LT recipients with autoimmune liver disease (ALD). Patients and Methods : Among 809 patients who underwent LT from January 2014 to December 2020, four ALD patients developed AMR, which was confirmed based on clinical features, histopathology of liver biopsy, donor-specific antibodies (DSA) or panel reactive antibody (PRA) level. Therapies were individualized based on clinical manifestations. Results : The incidence of acute AMR was 0.49%, and the incidence of acute AMR with ALD and non-ALD recipients was 11.1% and 0%, respectively. Three patients had strongly positive HLA class II DSA, and one patient was with the PRA class I and II sensitivities, which were >80%; complement component 4d (C4d) staining was negative in all patients. The first patient underwent re-LT, and the other three patients had good prognoses with treatments. Conclusions : ALD patients are prone to acute AMR after LT, thus should be kept vigilant against the occurrence of acute AMR.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- liver failure
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- drug induced
- respiratory failure
- multiple sclerosis
- risk assessment
- risk factors
- adipose tissue
- aortic dissection
- patient reported
- single molecule
- locally advanced
- rectal cancer